From nature to nanotech: Unlocking Berberine's therapeutic approaches

Chaudhari, S; Dalabehera, M; Subudhi, RN; Dua, K; Kaur, M; Paudel, KR; Kumar, J

From nature to nanotech: Unlocking Berberine's therapeutic approaches

Chaudhari, S Dalabehera, M Subudhi, RN Dua, K

Kaur, M Paudel, KR Kumar, J

Permalink

Publisher:: Elsevier
Publication Type:: Journal Article
Citation:: Journal of Drug Delivery Science and Technology, 2025, 108, pp. 106924
Issue Date:: 2025-06-01

Closed Access

	Filename	Description	Size
	From nature to nanotech- Unlocking Berberine's therapeutic approaches.pdf	Published version	5.06 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Chaudhari, S
dc.contributor.author	Dalabehera, M
dc.contributor.author	Subudhi, RN
dc.contributor.author	Dua, K https://orcid.org/0000-0002-7507-1159
dc.contributor.author	Kaur, M
dc.contributor.author	Paudel, KR
dc.contributor.author	Kumar, J
dc.date.accessioned	2025-05-05T01:24:12Z
dc.date.available	2025-05-05T01:24:12Z
dc.date.issued	2025-06-01
dc.identifier.citation	Journal of Drug Delivery Science and Technology, 2025, 108, pp. 106924
dc.identifier.issn	1773-2247
dc.identifier.uri	http://hdl.handle.net/10453/187179
dc.description.abstract	Despite being widely used, the therapeutic outcomes of Berberine (BBR)have remained suboptimal due to its poor aqueous solubility, absorption, rapid metabolism, and limited targeting. This results in pitiable bioavailability, which in turn demands frequent administration. The employment of a nanomaterials-based framework embedded with BBR could lessen the deprived pharmacokinetics and amplify the curative intervention. This manuscript delves into various nanomaterials and methods-based systems designed to address these drawbacks. Nanotechnology-based delivery systems, including magnetic, gold, selenium, and liposomal nanoparticles, as well as polymeric and mesoporous silica carriers, have demonstrated significant potential to overcome Berberine's pharmacokinetic limitations. These systems enhance bioavailability, provide targeted delivery, and offer sustained release, showing promising results in preclinical and clinical models for cancer, metabolic, and neurodegenerative disorders. The manuscript also frameworks an in-depth analysis of BBR's underlying pharmacological mechanism, various synergistic studies, clinical trials, and associated patent data. By employing nano-BBR with surface modification, we could sidestep the constraints of traditional forms by attenuating regrettable attributes of BBR. Implementation of combinatorial chemistry, in addition to the in-silico approach, might refine the clinical outcomes of BBR. However, steering into regulatory complexity is important, which may affect its market success because of its physiological drawbacks.
dc.language	en
dc.publisher	Elsevier
dc.relation.ispartof	Journal of Drug Delivery Science and Technology
dc.relation.isbasedon	10.1016/j.jddst.2025.106924
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	1115 Pharmacology and Pharmaceutical Sciences
dc.subject.classification	Pharmacology & Pharmacy
dc.subject.classification	3214 Pharmacology and pharmaceutical sciences
dc.title	From nature to nanotech: Unlocking Berberine's therapeutic approaches
dc.type	Journal Article
utslib.citation.volume	108
utslib.for	1115 Pharmacology and Pharmaceutical Sciences
pubs.organisational-group	University of Technology Sydney
pubs.organisational-group	University of Technology Sydney/Faculty of Health
pubs.organisational-group	University of Technology Sydney/Faculty of Science
pubs.organisational-group	University of Technology Sydney/UTS Groups
pubs.organisational-group	University of Technology Sydney/UTS Groups/Centre for Inflammation (CFI)
pubs.organisational-group	University of Technology Sydney/UTS Groups/Centre for Inflammation (CFI)/Centre for Inflammation (CFI) Associate Members
pubs.organisational-group	University of Technology Sydney/UTS Groups/Australian Research Consortium in Complementary and Integrative Medicine (ARCCIM)
pubs.organisational-group	University of Technology Sydney/UTS Groups/Stroke Research Collaborative
utslib.copyright.status	closed_access	*
dc.date.updated	2025-05-05T01:24:09Z
pubs.publication-status	Accepted
pubs.volume	108

Abstract:

Despite being widely used, the therapeutic outcomes of Berberine (BBR)have remained suboptimal due to its poor aqueous solubility, absorption, rapid metabolism, and limited targeting. This results in pitiable bioavailability, which in turn demands frequent administration. The employment of a nanomaterials-based framework embedded with BBR could lessen the deprived pharmacokinetics and amplify the curative intervention. This manuscript delves into various nanomaterials and methods-based systems designed to address these drawbacks. Nanotechnology-based delivery systems, including magnetic, gold, selenium, and liposomal nanoparticles, as well as polymeric and mesoporous silica carriers, have demonstrated significant potential to overcome Berberine's pharmacokinetic limitations. These systems enhance bioavailability, provide targeted delivery, and offer sustained release, showing promising results in preclinical and clinical models for cancer, metabolic, and neurodegenerative disorders. The manuscript also frameworks an in-depth analysis of BBR's underlying pharmacological mechanism, various synergistic studies, clinical trials, and associated patent data. By employing nano-BBR with surface modification, we could sidestep the constraints of traditional forms by attenuating regrettable attributes of BBR. Implementation of combinatorial chemistry, in addition to the in-silico approach, might refine the clinical outcomes of BBR. However, steering into regulatory complexity is important, which may affect its market success because of its physiological drawbacks.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/187179